Compare BEEM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | IGC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 31.2M |
| IPO Year | N/A | N/A |
| Metric | BEEM | IGC |
|---|---|---|
| Price | $1.69 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.00 | ★ $4.13 |
| AVG Volume (30 Days) | 208.3K | ★ 975.0K |
| Earning Date | 11-14-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,668,000.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | $45.61 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.25 |
| 52 Week High | $4.04 | $0.50 |
| Indicator | BEEM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 46.99 |
| Support Level | $1.62 | $0.28 |
| Resistance Level | $1.72 | $0.31 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 70.49 | 36.24 |
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.